# The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia

Study · id `cardio:ct-nct03944109` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03944109](<https://clinicaltrials.gov/study/NCT03944109>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03944109

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT03944109. Randomized; triple masking; primary purpose treatment. Start 2019-06-20 (actual); primary completion 2020-12-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT03944109, source copy `cardio:ctgov-nct03944109-2022-11-30`, retrieved 2026-10-31)
- Started: 2019-06-20 (actual) (ClinicalTrials.gov record NCT03944109, source copy `cardio:ctgov-nct03944109-2022-11-30`, retrieved 2026-10-31)
- Primary completion: 2020-12-22 (actual) (ClinicalTrials.gov record NCT03944109, source copy `cardio:ctgov-nct03944109-2022-11-30`, retrieved 2026-10-31)
- Completion: 2020-12-22 (actual) (ClinicalTrials.gov record NCT03944109, source copy `cardio:ctgov-nct03944109-2022-11-30`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03944109, source copy `cardio:ctgov-nct03944109-2022-11-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03944109-2022-11-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Safety, Tolerability and Efficacy of Multiple Subcutaneous Injections of SHR-1209 in Subjects With Hyperlipidemia
- Condition: Hyperlipidemia
- Intervention (Drug): SHR-1209
- Intervention (Drug): Placebo
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study (`cardio:pubmed-35039035`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 571385b91600e116219139258612d21c65ca4f6b8c379f00a9b0b0a370fec975
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
